Council on Radionuclides and Radiopharmaceuticals, Inc. Supports House Committee on Foreign Affairs on Actions to Reduce U.S. Reliance on Russian Nuclear Material
May 16 2024 - 8:30AM
The Council on Radionuclides and Radiopharmaceuticals, Inc.
(CORAR), applauds House Subcommittee on Europe Chairman Tom Kean
(R-NJ) and Ranking Member Bill Keatings (D-MA) for their leadership
in directing the passage of H.R. 8046, the “
Rosatom
Sanctions Enforcement Act.” This bipartisan bill
recognizes the importance of radioactive and enriched stable
isotopes for U.S. patients and industry.
According to the Society of Nuclear Medicine and Molecular
Imaging (SNMMI), more than 20 million Americans benefit each year
from nuclear medicine procedures.1 Nuclear medicine procedures in
the U.S. utilize radiopharmaceuticals (radioactive drugs) to
diagnose and treat conditions like cancer, heart disease, and
dementia. They rely on specific radioactive isotopes and, at times,
enriched stable isotopes to produce the radioactive isotopes. In
addition, radioactive and enriched stable isotopes are necessary
for many U.S. industrial applications and safety
products.
“H.R. 8046 provides options to secure essential medical and
industrial radioactive and stable enriched isotope supplies during
the U.S. shift to domestic production, guaranteeing a dependable
and sustainable supply for patients and industries. CORAR is eager
to collaborate with the Congress to advance this crucial
legislation,” said Michael J. Guastella, CORAR Executive
Director.
About CORAR: The Council on Radionuclides and
Radiopharmaceuticals, Inc. is a Washington, DC based trade
association that is a leading voice of the radionuclide,
radiopharmaceutical, and industrial radioisotope industries in
North America. CORAR represents the major manufacturers and
distributors of radiopharmaceuticals, radioactive sources and
medical isotopes primarily used in the United States for
therapeutic and diagnostic nuclear medical applications (referred
to as nuclear medicine) and, in some cases, for industrial,
environmental, and biomedical research and quality control.
http://www.corar.org
Michael J. Guastella, MS, MBAExecutive Director500 North Capitol
Street, NWSuite 210Washington, DC 20001-7407(202) 547-6582Fax:
(202) 547-4658michael.guastella@corar.org
1 Society of Nuclear Medicine and Molecular Imaging,
http://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=4825